Overview

Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

Status:
Not yet recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well canakinumab and azacitidine work for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Immunotherapy with canakinumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as azacitidine works in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving canakinumab and azacitidine may work better in controlling the disease.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Azacitidine